DMKN (dermokine) is a secreted protein with isoform-specific roles in keratinocyte differentiation and skin barrier function. The epidermis-restricted α, β, and γ isoforms are produced through alternative polyadenylation, with β and γ isoforms specifically expressed in granular keratinocytes 1. DMKN acts as a soluble regulator of keratinocyte differentiation and participates in cornified envelope assembly 1. Functionally, DMKN β and γ isoforms are essential for proper cornification; mice deficient in these isoforms display transient scaly skin with smaller keratohyalin granules and cornified envelopes more sensitive to mechanical stress, though compensatory overexpression of DMKN α partially masks the phenotype 1. Clinically, DMKN has emerged as a disease-relevant gene in multiple contexts. Whole exome sequencing identified DMKN as a candidate gene linked to human phenotypes in a large diagnostic cohort 2. In melanoma, elevated DMKN expression correlates with poor overall survival, particularly in BRAF-mutated samples, with somatic loss-of-function mutations (p.E69D and p.V91A) identified in advanced melanoma patients 3. DMKN dysregulation modulates epithelial-mesenchymal transition through ERK/MAPK signaling pathways 3. Additionally, DMKN methylation changes occur in monocyte exhaustion following sepsis, suggesting immune system involvement 4. DMKN expression is also regulated as an alternative splicing target in osteosarcoma development 5.